A GPCR/secretase complex regulates β- And γ-secretase specificity for Aβ production and contributes to AD pathogenesis

Cell Research

Volumn 20, Issue 2, 2010, Pages 138-153

  Teng, Lin ^a,b   Zhao, Jian ^a,b   Wang, Feifei ^c   Ma, Lan ^c   Pei, Gang ^a,b,d  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c FUDAN UNIVERSITY   (China)

^d TONGJI UNIVERSITY   (China)

Author keywords

Alzheimer's disease; BACE; G protein coupled receptor; Notch; Secretase

Indexed keywords

AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; CARBAMIC ACID DERIVATIVE; DELTA OPIATE RECEPTOR; DIPEPTIDE; DRUG DERIVATIVE; ENKEPHALIN[2 ALANINE 5 LEUCINE]; G PROTEIN COUPLED RECEPTOR; L 685458; MULTIPROTEIN COMPLEX; NALTREXONE; NALTRINDOLE; NARCOTIC ANTAGONIST; SECRETASE;

ALZHEIMER DISEASE; ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; TRANSGENIC MOUSE; TRANSPORT VESICLE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CARBAMATES; CELLS, CULTURED; DIPEPTIDES; ENKEPHALIN, LEUCINE-2-ALANINE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; NALTREXONE; NARCOTIC ANTAGONISTS; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, DELTA; SUBSTRATE SPECIFICITY; TRANSPORT VESICLES;

MUS;

EID: 76449102392     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.3     Document Type: Article

References (67)

1. Albert MS. Cognitive and neurobiologic markers of early Alzheimer disease. Proc Natl Acad Sci USA 1996; 93:13547-13551.
2. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997; 275:630-631.
3. Selkoe DJ. Deciphering the genesis and fate of amyloid protein yields novel therapies for Alzheimer disease. J Clin Invest 2002; 110:1375-1381.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
5. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32:177-180.
6. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987; 325:733-736.
7. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein secretase from human brain. Nature 1999; 402:537-540.
8. Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 2003; 422:438-441.
9. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286:735-741.
10. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999; 96:11049-11053.
11. De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. Neuron 2003; 38:9-12.
12. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalaninescanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA 1999; 96:3053-3058.
13. Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol 2003; 35:1505-1535.
14. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001; 292:1550-1552.
15. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003; 100:4162-4167.
16. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease β-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003; 278:2081-2084.
17. Hemming ML, Selkoe DJ. Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280:37644-37650.
18. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368:387-403.
19. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258:304-307.
20. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med 1998; 4:447-451.
21. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414:212-216.
22. Cai D, Netzer WJ, Zhong M, et al. Presenilin-1 uses phospholipase D1 as a negative regulator of β-amyloid formation. Proc Natl Acad Sci USA 2006; 103:1941-1946.
23. Ni Y, Zhao, X, Bao G, et al. Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation. Nat Med 2006; 12:1390-1396.
24. Thathiah A, Spittaels K, Hoffmann M, et al. The orphan G protein-coupled receptor 3 modulates amyloid-βpeptide generation in neurons. Science 2009; 323:946-951.
25. Bramham CR, Milgram NW, Srebro B. Delta opioid receptor activation is required to induce LTP of synaptic transmission in the lateral perforant path in vivo. Brain Res 1991; 567:42-50.
26. Wagner JJ, Terman GW, Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993; 363:451-454.
27. Gallagher M, King RA, Young NB. Opiate antagonists improve spatial memory. Science 1983; 221:975-976.
28. Izquierdo I, Paiva AC, Elisabetsky E. Post-training intraperitoneal administration of leu-enkephalin and endorphin causes retrograde amnesia for two different tasks in rats. Behav Neural Biol 1980; 28:246-250.
29. Reisberg B, Ferris SH, Anand R, et al. Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med 1983; 308:721-722.
30. Tariot PN, Sunderland T, Murphy DL, et al. Design and interpretation of opiate antagonist trials in dementia. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10:611-626.
31. Pomara N, Roberts R, Rhiew HB, Stanley M, Gershon S. Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease. Neurobiol Aging 1985; 6:233-236.
32. Serby M, Resnick R, Jordan B, Adler J, Corwin J, Rotrosen JP. Naltrexone and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986; 10:587-590.
33. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002; 66:285-306.
34. Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. Mu-, delta- and κ-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res 2001; 893:121-134.
35. Risser D, You ZB, Cairns N, et al. Endogenous opioids in frontal cortex of patients with Down syndrome. Neurosci Lett 1996; 203:111-114.
36. Meilandt WJ, Yu GQ, Chin J, et al. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008; 28:5007-5017.
37. Marks N, Berg MJ. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem Int 2008; 52:184-215.
38. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393:382-386.
39. Karlstrom H, Bergman A, Lendahl U, Naslund J, Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J Biol Chem 2002; 277:6763-6766.
40. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007; 8:128-140.
41. Sargiacomo M, Lisanti M, Graeve L, Le Bivic A, Rodriguez- Boulan E. Integral and peripheral protein composition of the apical and basolateral membrane domains in MDCK cells. J Membr Biol 1989; 107:277-286.
42. von Arnim CA, Tangredi MM, Peltan ID, et al. Demonstration of BACE (γ-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 2004; 117:5437-5445.
43. Kaether C, Lammich S, Edbauer D, et al. Presenilin-1 affects trafficking and processing of βAPP and is targeted in a complex with nicastrin to the plasma membrane. J Cell Biol 2002; 158:551-561.
44. Whistler JL, Enquist J, Marley A, et al. Modulation of postendocytic sorting of G protein-coupled receptors. Science 2002; 297:615-620.
45. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001; 32:829-839.
46. Afify EA, Law PY, Riedl M, Elde R, Loh HH. Role of carboxyl terminus of mu-and κ-opioid receptor in agonist-induced down-regulation. Brain Res Mol Brain Res 1998; 54:24-34.
47. Portoghese PS, Sultana M, Takemori AE. Naltrindole, a highly selective and potent non-peptide δ opioid receptor antagonist. Eur J Pharmacol 1988; 146:185-186.
48. Ward SJ, Portoghese PS, Takemori AE. Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine. J Pharmacol Exp Ther 1982; 220:494-498.
49. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73:953-990.
50. Dhawan BN, Cesselin F, Raghubir R, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48:567-592.
51. Fernandez B, Antelo MT, Kitchen I, Viveros MP. Effects of neonatal naltrindole treatment on antinociceptive and behavioral responses to mu and kappa agonists in rats. Pharmacol Biochem Behav 1999; 62:145-149.
52. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001; 17:157-165.
53. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006; 24:516-524.
54. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe + PSEN1δE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 2007; 6:54-65.
55. Kitchen I, Pinker SR. Antagonism of swim-stress-induced antinociception by the κ-opioid receptor antagonist naltrindole in adult and young rats. Br J Pharmacol 1990; 100:685-688.
56. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by δ(9)- tetrahydrocannabinol. Psychopharmacology (Berl) 2002; 163:111-117.
57. Matsuzawa S, Suzuki T, Misawa M, Nagase H. Involvement of mu- and κ-opioid receptors in the ethanol-associated place preference in rats exposed to foot shock stress. Brain Res 1998; 803:169-177.
58. Negus SS, Henriksen SJ, Mattox A, et al. Effect of antagonists selective for mu, δ and κ opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther 1993; 265:1245-1252.
59. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 2007; 282:36275-36282
60. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987; 79:195-200.
61. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49:489-502.
62. Eggert S, Paliga K, Soba P, et al. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves α-,β-, γ-, and epsilon-like cleavages: modulation of APLP-1 processing by N-glycosylation. J Biol Chem 2004; 279:18146-18156.
63. Chishti MA, Yang DS, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276:21562-21570.
64. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100:183-188.
65. Westerman MA, Cooper-Blacketer D, Mariash A, et al. The relationship between A and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2002; 22:1858-1867.
66. Lazarov O, Robinson J, Tang YP, et al. Environmental enrichment reduces A levels and amyloid deposition in transgenic mice. Cell 2005; 120:701-713.
67. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Naslund J. Partial purification and characterization of γ-secretase from post-mortem human brain. J Biol Chem 2003; 278:24277-24284.